| RS2039242108 |
BCKDHA
|
Health Risk |
Pathogenic/Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 1A |
| RS2039242789 |
BCKDHA
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2039243107 |
POLD1
|
Health Risk |
Conflicting classifications of pathogenicity |
Colorectal cancer, susceptibility to |
| RS2039246253 |
POLD1
|
Health Risk |
Conflicting classifications of pathogenicity |
Colorectal cancer, susceptibility to |
| RS2039246325 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2039246615 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2039247540 |
BCKDHA
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 1A |
| RS2039248188 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2039250790 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2039254077 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2039260502 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2039260545 |
FANCA
|
Health Risk |
Likely pathogenic |
Fanconi anemia, Abnormality of blood and blood-forming tissues |
| RS2039260856 |
FANCA
|
Health Risk |
Pathogenic/Likely pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2039261208 |
GAA
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease, type II |
| RS2039261436 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2039261844 |
FANCA
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2039262153 |
FANCA
|
Health Risk |
Conflicting classifications of pathogenicity |
Fanconi anemia, Fanconi anemia complementation group A |
| RS2039263207 |
FANCA
|
Health Risk |
Conflicting classifications of pathogenicity |
Fanconi anemia, Inborn genetic diseases |
| RS2039265074 |
POLD1
|
Health Risk |
Conflicting classifications of pathogenicity |
Colorectal cancer, susceptibility to |
| RS2039266434 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2039267300 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2039275157 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2039275264 |
FANCA
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group A, Fanconi anemia |
| RS2039275333 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2039276663 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2039278551 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia |
| RS2039278966 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2039280842 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2039284438 |
BCKDHA
|
Health Risk |
Conflicting classifications of pathogenicity |
Maple syrup urine disease, Maple syrup urine disease |
| RS2039285328 |
BCKDHA
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2039287628 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2039287852 |
GAA
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease, type II |
| RS2039289668 |
FANCA
|
Health Risk |
Pathogenic/Likely pathogenic |
Fanconi anemia, Fanconi anemia complementation group A |
| RS2039289942 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2039290343 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2039292050 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2039292320 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2039300041 |
HID1
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy 105 with hypopituitarism, Developmental and epileptic encephalopathy 105 with hypopituitarism |
| RS2039304656 |
ZFYVE26
|
Health Risk |
Pathogenic |
Spastic paraplegia, Spastic paraplegia |
| RS2039307447 |
ZFYVE26
|
Health Risk |
Likely pathogenic |
Spastic paraplegia, Spastic paraplegia |
| RS2039309312 |
CIITA
|
Health Risk |
Likely pathogenic |
MHC class II deficiency, MHC class II deficiency |
| RS2039321844 |
CEP290
|
Health Risk |
Pathogenic |
Joubert syndrome, Nephronophthisis |
| RS2039327767 |
POLD1
|
Health Risk |
Conflicting classifications of pathogenicity |
Colorectal cancer, susceptibility to |
| RS2039330078 |
FANCA
|
Health Risk |
Conflicting classifications of pathogenicity |
Fanconi anemia, Fanconi anemia complementation group A |
| RS2039330307 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2039331837 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2039333225 |
ZFYVE26
|
Health Risk |
Pathogenic |
Spastic paraplegia, Spastic paraplegia |
| RS2039334639 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2039335473 |
POLD1
|
Health Risk |
Conflicting classifications of pathogenicity |
Colorectal cancer, susceptibility to |
| RS2039335667 |
ZFYVE26
|
Health Risk |
Pathogenic |
Spastic paraplegia, Spastic paraplegia |
| RS2039336515 |
SLC7A7
|
Health Risk |
Pathogenic |
Lysinuric protein intolerance, Lysinuric protein intolerance |
| RS2039339156 |
POLD1
|
Health Risk |
Conflicting classifications of pathogenicity |
Mandibular hypoplasia-deafness-progeroid syndrome, Mandibular hypoplasia-deafness-progeroid syndrome |
| RS2039339219 |
SLC7A7
|
Health Risk |
Pathogenic |
Lysinuric protein intolerance, Lysinuric protein intolerance |
| RS2039344714 |
SLC7A7
|
Health Risk |
Pathogenic |
Lysinuric protein intolerance, Lysinuric protein intolerance |
| RS2039349935 |
SLC7A7
|
Health Risk |
Pathogenic |
Lysinuric protein intolerance, Lysinuric protein intolerance |
| RS2039364779 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2039364798 |
CEP290
|
Health Risk |
Pathogenic |
Joubert syndrome, Meckel-Gruber syndrome |
| RS2039371081 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2039372961 |
BCKDHA
|
Health Risk |
Pathogenic/Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 1A |
| RS2039375116 |
BCKDHA
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2039375435 |
BCKDHA
|
Health Risk |
Pathogenic |
— |
| RS2039381583 |
BCKDHA
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2039382789 |
BCKDHA
|
Health Risk |
Conflicting classifications of pathogenicity |
Maple syrup urine disease, Maple syrup urine disease type 1A |
| RS2039383036 |
BCKDHA
|
Health Risk |
Pathogenic/Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 1A |
| RS2039383167 |
GAA
|
Health Risk |
Conflicting classifications of pathogenicity |
Glycogen storage disease, type II |
| RS2039386741 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia |
| RS2039389205 |
GAA
|
Health Risk |
Pathogenic |
— |
| RS2039389302 |
BCKDHA
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2039389744 |
GAA
|
Health Risk |
Pathogenic |
— |
| RS2039397653 |
MEGF8
|
Health Risk |
Likely pathogenic |
MEGF8-related Carpenter syndrome, MEGF8-related Carpenter syndrome |
| RS2039403673 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2039405116 |
BCKDHA
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 1A |
| RS2039407382 |
BCKDHA
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2039415511 |
GAA
|
Health Risk |
Conflicting classifications of pathogenicity |
Glycogen storage disease, type II |
| RS2039418269 |
GAA
|
Health Risk |
Conflicting classifications of pathogenicity |
Glycogen storage disease, type II |
| RS2039434309 |
MTM1
|
Health Risk |
Likely pathogenic |
Severe X-linked myotubular myopathy, Severe X-linked myotubular myopathy |
| RS2039444431 |
ATP8A2
|
Health Risk |
Pathogenic |
— |
| RS2039462341 |
ZFYVE26
|
Health Risk |
Likely pathogenic |
Spastic paraplegia, Spastic paraplegia |
| RS2039462773 |
ZFYVE26
|
Health Risk |
Conflicting classifications of pathogenicity |
Spastic paraplegia, Hereditary spastic paraplegia |
| RS2039463765 |
ZFYVE26
|
Health Risk |
Pathogenic |
Spastic paraplegia, Spastic paraplegia |
| RS2039485066 |
ATL1
|
Health Risk |
Likely pathogenic |
Hereditary spastic paraplegia 3A, Hereditary spastic paraplegia 3A |
| RS2039494684 |
HID1
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy 105 with hypopituitarism, Developmental and epileptic encephalopathy 105 with hypopituitarism |
| RS2039524843 |
CACNA1G
|
Health Risk |
Likely pathogenic |
Spinocerebellar ataxia type 42, Spinocerebellar ataxia type 42 |
| RS2039539459 |
ATL1
|
Health Risk |
Pathogenic/Likely pathogenic |
Inborn genetic diseases, Hereditary spastic paraplegia 3A |
| RS2039539616 |
SETD2
|
Health Risk |
Conflicting classifications of pathogenicity |
Luscan-Lumish syndrome, Inborn genetic diseases |
| RS2039539644 |
ATL1
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary spastic paraplegia, Hereditary spastic paraplegia 3A |
| RS2039543082 |
ATL1
|
Health Risk |
Pathogenic |
Hereditary spastic paraplegia 3A, Hereditary spastic paraplegia 3A |
| RS2039543383 |
ZFYVE26
|
Health Risk |
Pathogenic |
Spastic paraplegia, Spastic paraplegia |
| RS2039544464 |
ZFYVE26
|
Health Risk |
Likely pathogenic |
Hereditary spastic paraplegia 15, Hereditary spastic paraplegia 15 |
| RS2039593666 |
ZFYVE26
|
Health Risk |
Pathogenic |
Spastic paraplegia, Spastic paraplegia |
| RS2039600745 |
GCH1
|
Health Risk |
Conflicting classifications of pathogenicity |
Dystonia 5, GTP cyclohydrolase I deficiency |
| RS2039603867 |
FANCA
|
Health Risk |
Likely pathogenic |
Fanconi anemia, Fanconi anemia complementation group A |
| RS2039604081 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2039605345 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2039605605 |
FANCA
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group A, Fanconi anemia |
| RS2039612615 |
MYH11
|
Health Risk |
Conflicting classifications of pathogenicity |
Aortic aneurysm, familial thoracic 4 |
| RS2039613696 |
ZFYVE26
|
Health Risk |
Pathogenic |
Spastic paraplegia, Hereditary spastic paraplegia 15 |
| RS2039614529 |
USH2A
|
Health Risk |
Pathogenic |
Usher syndrome type 2A, Retinitis pigmentosa 39 |
| RS2039616151 |
ZFYVE26
|
Health Risk |
Pathogenic |
Spastic paraplegia, Spastic paraplegia |
| RS2039616380 |
USH2A
|
Health Risk |
Pathogenic |
Usher syndrome type 2, Usher syndrome type 2 |